No profile data available.
Abpro Holdings, Inc. (ABP) is a healthcare company in the additional cancer treatment drugs industry, based in Woburn, United States, with about 6 full-time employees.
It reported revenue of $183,000 for fiscal year 2024, up 50.0% from fiscal year 2023, and net income of -$17.41 million. In Q2 2025 (the quarter ended June 30, 2025) revenue was $0. Its market capitalization was $17.30 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of December 4, 2025.
, a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology.
Abpro reported $183,000 in revenue for fiscal year 2024, up 50.0% from $122,000 in fiscal year 2023. In Q2 2025 revenue was $0.
$17.30 million as of December 4, 2025.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Shuttle Pharmaceuticals Holdings, Inc. (SHPH), Akari Therapeutics, Plc (AKTX), Curis, Inc. (CRIS), Allarity Therapeutics, Inc. (ALLR).